Biopharmaceutical company Poolbeg Pharma plc (AIM: POLB) announced on Wednesday that it has secured a US patent for its Immunomodulator I application, bolstering its intellectual property portfolio.

The granted claims cover POLB 001, a Phase II-ready, potent p38 MAP kinase inhibitor, for treating severe influenza-related hypercytokinemia (cytokine storm) and reducing risks associated with severe immune responses.

This addition complements existing patents for POLB 001 and p38 MAP kinase inhibitors in severe influenza treatment and cytokine release syndromes induced by cancer immunotherapies. Poolbeg is actively expanding its patent portfolio to enhance the value and partnership potential of POLB 001 and related assets.

Focused on innovative therapies for rare diseases and unmet medical needs, Poolbeg continues to build a robust pipeline of development assets aimed at improving patient outcomes.